Savara stock: Savara presents CHEST data before FDA decision for Savara stock

Published on 10/24/2026 at 01:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CHEST data dated October 21, 2026 covered molgramostim. Savara stock faces November 22, 2026 FDA decision on MOLBREEVI after a three-month review extension.

Regulatory dates shape Savara

Savara presented molgramostim findings at CHEST on October 21, 2026.
Second-quarter adjusted earnings per share were USD -0.16 versus USD -0.14 expected.
The next results date is November 11, 2026, followed by the FDA decision on November 22, 2026.
Savara had USD 867.0 million in market capitalization as of October 23, 2026.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara (ISIN US8051111016) presented new molgramostim data at the CHEST 2026 meeting on October 21, 2026, according to MarketScreener. The next regulatory marker is the November 22, 2026 FDA decision on MOLBREEVI for autoimmune pulmonary alveolar proteinosis, listed by RTTNews.

Three milestones set the test

On April 15, 2026, Savara said the FDA extended the review period by three months to November 22, 2026, according to MarketScreener. On August 11, 2026, Savara reported second-quarter adjusted earnings per share of USD -0.16 versus USD -0.14 expected, according to MarketBeat. On October 21, 2026, the company presented a post-hoc analysis from the IMPALA trial at CHEST 2026, including eight patients receiving daily molgramostim and three receiving placebo, according to MarketScreener.

What does the data mean for approval?

The subgroup analysis found that mean alveolar-arterial oxygen gradient improved by 12.7 millimeters of mercury from baseline to Week 24 for molgramostim patients, compared with 0.3 millimeters of mercury for placebo. The source described the findings as exploratory because the subgroup contained only 13 patients, which limits how directly the result can inform the pending FDA decision. Savara remains a clinical-stage biotechnology company focused on rare respiratory diseases, with molgramostim as its lead program.

Two dates frame the next test

Savara's next quarterly results are listed for November 11, 2026, by Forecaster. The FDA decision on MOLBREEVI is scheduled for November 22, 2026, according to RTTNews.

Regulatory timing dominates

Savara's near-term picture is defined by the November decision and the cash and operating update due with third-quarter results. The company had a market capitalization of USD 867.0 million as of October 23, 2026, while its primary listing is on Nasdaq. The further course of trading is shown by the continuously updated real-time quote of Savara stock.